Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma.

Next Previous
Trial Profile

Revlimid to Augment Efficacy of Prevnar Vaccines in Patients With Relapsed or Refractory Myeloma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacodynamics

Most Recent Events

  • 23 Jul 2015 Primary endpoints been amended.
  • 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov reccord.
  • 12 Jan 2012 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top